Galena Biopharma Inducts Mary Ann Gray To Its Board

Galena Biopharma, Inc.

revealed that Mary Ann Gray was inducted to its Board of Directors with immediate effective. According to the company, Gray would be listed in Galena's 2016 Proxy and would be a nominee for election, at its Annual Meeting of Stockholders. The company's President and CEO, Mark Schwartz, said, "We are delighted to welcome Mary Ann Gray to our Board of Directors where her scientific background, positions at leading pharmaceutical companies and institutions, and her buy-side and sell-side experience will have an invaluable impact on the success of Galena. Dr. Gray is our first female board member, adding new perspectives to our Board as we continue to expand our portfolio of women's oncology indications. She has been a champion of NeuVax™ for many years, and we look forward to her guidance and expertise as we advance our programs." Galena Biopharma said that Gray has an extensive background both as a scientist and an analyst apart from portfolio manager for more than $1 billion in healthcare investments. The company added that she was an experienced corporate director for both public and private companies encompassing every stage of development from pre-clinical to commercial. For her part, Gray said, "Since my academic career, I have maintained a focus in oncology, and I am thrilled to bring this passion to Galena as a member of the Board of Directors. As a long-term shareholder in the Company, I have believed in NeuVax for over seven years and have closely monitored its development from an early stage asset to its now significantly expanded portfolio of clinical trials. I am grateful for this opportunity to join the company at this critical time as NeuVax is approaching its pivotal endpoint," On Monday, the stock shed 1.4%.